| 发明名称 | Selective cartilage therapy | ||
| 摘要 | The present invention relates to compositions, methods and kits for delivery of an IGF-1 protein or a functional fragment or variant, derivative thereof to cells or tissues that express proteoglycans. More specifically, the present invention relates to fusion proteins comprising a heparin binding protein (HB) comprising SEQ ID NO: 1 or SEQ ID NO: 2. Other aspects relate to use of a HB-IGF-1 fusion proteins in methods to deliver IGF-1 to the cartilage for the treatment of a cartilage related disease and disorder in a subject. | ||
| 申请公布号 | US9637531(B2) | 申请公布日期 | 2017.05.02 |
| 申请号 | US201314409312 | 申请日期 | 2013.06.25 |
| 申请人 | The Brigham and Women's Hospital, Inc | 发明人 | Lee Richard T.;Patwari Parth;Loffredo Francesco;Pancoast James;Dong Zheng Xin;Vannelli Todd |
| 分类号 | C07K14/65;C07K7/00;C07K14/475;A61K38/30;C07K14/47 | 主分类号 | C07K14/65 |
| 代理机构 | Brown Rudnick LLP | 代理人 | Brown Rudnick LLP ;Meyers Thomas C. |
| 主权项 | 1. A composition comprising a HB-X fusion protein, wherein HB is a heparin binding peptide having the amino acid sequence (MKRKKKGKGLGKKRDPSLRKYK) (SEQ ID NO:1) or (KRKKKGKGLGKKRDPSLRKYK) (SEQ ID NO:2), and X is Insulin-like growth factor 1 (IGF-1), and further wherein the IGF-1 is a human IGF-1. | ||
| 地址 | Boston MA US | ||